Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease: K-ELUVIA Registry

Abstract

Author's summary The K-ELUVIA study assessed Eluvia™, a paclitaxel-eluting stent, in treating femoropopliteal artery disease across 7 Korean centers. Enrolling 105 patients undergoing endovascular treatment, our prospective 2-year study revealed promising outcomes. Clinical patency at 2 years stood at 76.3%, with freedom from target lesion revascularization at 79.1%. Noteworthy predictors of clinical patency loss included chronic total occlusion and stent diameter. This study affirms Eluvia’s favorable clinical outcomes in real-world femoropopliteal interventions.